Atasin 20 mg Tablet (Atorvastatin) – ACI Limited

1. About Atasin 20 mg (Atorvastatin)

Atasin 20 mg Tablet contains Atorvastatin Calcium 20 mg, a moderate-intensity statin manufactured by ACI Limited, Bangladesh. The 20 mg dose is standard for patients who require greater LDL-C reduction than the 10 mg starting dose, providing approximately 39–43% LDL-cholesterol reduction. It is appropriate for patients at moderate-to-high cardiovascular risk, including T2DM patients with additional risk factors, and those being titrated up from 10 mg.

Atorvastatin at 20 mg is classified as "moderate-intensity" statin therapy per ACC/AHA and ESC guidelines, achieving ≥30% LDL-C reduction. It bridges the gap between the standard starting dose (10 mg) and high-intensity therapy (40–80 mg), making it a commonly prescribed maintenance dose in Bangladesh's cardiovascular and diabetic patient populations.

2. Mechanism of Action

Atorvastatin selectively and competitively inhibits HMG-CoA reductase, the enzyme catalysing the conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate — the committed, rate-limiting step of hepatic cholesterol synthesis. Inhibition reduces hepatic cholesterol, upregulates LDL receptors, and clears circulating LDL-C and VLDL. At 20 mg, the pharmacodynamic effect (39–43% LDL-C reduction) reflects near-maximal receptor upregulation achievable at moderate dose.

Pleiotropic effects include hsCRP reduction, improved endothelial NO bioavailability, macrophage foam-cell formation inhibition, and reduced platelet aggregation — contributing to plaque stabilisation independent of LDL-C lowering.

3. Indications

• Moderate-intensity LDL-C reduction: For patients requiring 30–40% LDL-C lowering
• T2DM dyslipidaemia: Patients aged ≥40 with additional risk factors (hypertension, CKD, microalbuminuria, early CVD)
• Primary cardiovascular prevention: Moderate-to-high 10-year CVD risk (QRISK ≥10%)
• Secondary prevention: Post-MI or ACS where 40–80 mg is not tolerated; or when LDL targets are met at 20 mg
• Dose titration step: Titration from 10 mg when LDL target not achieved

4. Dosage and Administration

Dose: 20 mg once daily, any time of day. Atorvastatin's 14-hour half-life (20–30h including active metabolites) provides round-the-clock HMG-CoA inhibition regardless of dosing time. Take consistently at the chosen time for best adherence.

Titration: If starting at 10 mg and LDL target not achieved at 6–8 weeks, increase to 20 mg. If 20 mg insufficient, increase to 40 mg. Dose range 10–80 mg/day. No renal dose adjustment required.

5. Contraindications

• Active liver disease or unexplained persistent transaminase elevation
• Pregnancy and breastfeeding (teratogenic — Category X)
• Hypersensitivity to atorvastatin or excipients

6. Warnings and Precautions

Myopathy/Rhabdomyolysis: Risk increases with dose. At 20 mg, myalgia incidence (~5–10%). Elevated risk with concurrent CYP3A4 inhibitors (clarithromycin, itraconazole, diltiazem), cyclosporine, gemfibrozil, elderly, hypothyroidism, renal impairment. Stop immediately if severe myalgia + elevated CK or myoglobinuria.

Hepatic: Monitor LFTs at baseline and if symptomatic. Avoid in active hepatic disease. Alcohol increases hepatotoxicity risk.

New-onset DM: Modest risk in non-diabetic patients. Greatly outweighed by CV benefit. Does not affect existing T2DM management benefit.

Pregnancy: Effective contraception mandatory in women of childbearing potential. Stop immediately if pregnancy occurs.

7. Side Effects

Common: Myalgia, nasopharyngitis, arthralgia, headache, nausea, constipation, flatulence, insomnia, elevated CPK.

Uncommon: Elevated transaminases, peripheral oedema, alopecia, rash, decreased libido.

Rare: Rhabdomyolysis, immune-mediated necrotising myopathy (IMNM), hepatitis, pancreatitis, lupus-like syndrome.

8. Drug Interactions

• CYP3A4 inhibitors: Clarithromycin, erythromycin, itraconazole, ketoconazole, HIV protease inhibitors, diltiazem — increase atorvastatin exposure, use lowest dose or avoid
• Cyclosporine: OATP1B1 inhibition → markedly increases atorvastatin levels; max 10 mg with cyclosporine
• Gemfibrozil: Increased myopathy risk — avoid; use fenofibrate if fibrate needed
• Colchicine: Additive myopathy risk — caution
• Warfarin: Mild INR potentiation — monitor at initiation/dose change
• Rifampicin: Strong CYP3A4 inducer — reduces atorvastatin efficacy; consider dose adjustment

9. Atorvastatin 20 mg in Bangladesh Clinical Practice

In Bangladesh, the 20 mg dose is commonly used as maintenance therapy after titrating from 10 mg, and as the starting dose for higher-risk patients (T2DM + hypertension, T2DM + CKD stage 1–2, post-ACS early convalescence). Most BDEA and BCS Cardiology Society guidance aligns with ACC/AHA intensity categories: 20 mg is moderate-intensity, appropriate for primary prevention at moderate CVD risk. High-intensity therapy (40–80 mg) is reserved for established ASCVD, very-high-risk T2DM, familial hypercholesterolaemia, and acute coronary syndromes.

10. Storage

• Store below 30°C, dry place, protected from light and moisture. Keep in original blister packaging. Keep out of reach of children.

Frequently Asked Questions (FAQ)

Q1: How much does Atasin 20 mg (Atorvastatin) reduce cholesterol?

Atasin 20 mg (Atorvastatin 20 mg) by ACI Limited provides approximately 39–43% reduction in LDL-cholesterol. This is classified as "moderate-intensity" statin therapy per ACC/AHA 2018 and ESC/EAS 2019 guidelines. For context: Atasin 10 mg reduces LDL ~30–35%; Atasin 40 mg reduces ~46–51%; Atasin 80 mg reduces ~50–55%. If LDL target (e.g. <1.8 mmol/L for high-risk patients) is not reached at 20 mg after 6–8 weeks, the dose is typically increased to 40 mg.

Q2: Is Atasin 20 mg suitable for diabetic patients?

Yes — Atasin 20 mg (Atorvastatin) is very commonly prescribed for T2DM patients in Bangladesh. All T2DM patients aged ≥40 should be on statin therapy (ADA, IDF, BDEA). The 20 mg dose is appropriate for T2DM patients at moderate-to-high cardiovascular risk with additional risk factors. ACI's Atasin provides a quality-assured, affordable atorvastatin option. Note that statins modestly increase new-onset T2DM risk in non-diabetics (~10% relative risk), but existing T2DM patients are already diabetic — the cardiovascular benefit of statin therapy is unambiguously positive in this population.

Q3: Can Atasin 20 mg be taken with food?

Yes — atorvastatin can be taken with or without food. Food has minimal effect on atorvastatin absorption (Cmax slightly reduced with high-fat meal but AUC unaffected — clinical efficacy unchanged). Take Atasin 20 mg at any time of day, with or without food, at a consistent time for best adherence. Unlike some medications, evening dosing is not required — atorvastatin's long half-life provides 24-hour inhibition.

Q4: What happens if I miss a dose of Atasin 20 mg?

If you miss a dose, take it as soon as you remember — unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular schedule. Do not double-dose. Missing an occasional dose has minimal impact on long-term lipid control given atorvastatin's ~14-hour half-life and the cumulative nature of LDL receptor upregulation. However, consistent daily use is important for sustained cardiovascular protection.